BBOT - NASDAQ

BridgeBio Oncology Therapeutics Inc.

BBOT·NASDAQ

$8.19

-0.97%

HealthcareBiotechnology

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$656.08M

EPS-4.3000

P/E Ratio-1.90

Earnings Date06/04/2026

No Revenue Data

BBOT has not reported any revenue values in the available annual periods.

-134.04M

Net Income

80%

3Y+3807968.0%

5Y+309063.0%

10Y+309063.0%

-113.89M

Operating Cash Flow

14811%

3Y-

5Y-

10Y-

BridgeBio Oncology Therapeutics Inc. Profit Bridge

BBOT · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (610.00K)

Gross Profit-610.00K

Operating Expenses

Operating Expenses (145.82M)

Operating Income-145.82M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense11.78M

Pretax Income-134.04M

Income Tax (0.00)

Net Income-134.04M

Net Income

-134.04M

Profitability Analysis

BridgeBio Oncology Therapeutics Inc. Income Statement

BBOT • NASDAQ

BridgeBio Oncology Therapeutics Inc. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
REVENUE
GROSS PROFIT
Cost of Revenue	(610K)	(0.0)	(0.0)	(0.0)	(0.0)
Gross Profit	-610K	0.0	0.0	0.0	0.0
OPERATING INCOME
Operating Expenses	(145.8M)	(80.9M)	(64.8M)	(3.5K)	(43.4K)
Selling, General & Administrative	(24.6M)	(7.8M)	(8.5M)	(3.5K)	(43.4K)
Research & Development	(121.2M)	(73.1M)	(56.3M)	(0.0)	(0.0)
Operating Income	-145.8M	-80.9M	-64.8M	-3.5K	-43.4K
PRE-TAX INCOME
Net Interest Income	11.3M	8.5M	72K	0.0	0.0
Total Other Income Expenses Net	11.8M	8.2M	72K	0.0	0.0
Income Before Tax	-134M	-74.3M	-64.7M	-3.5K	-43.4K
NET INCOME
Net Income	-134M	-74.3M	-64.7M	-3.5K	-43.4K

SEC Filings

BBOT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 27, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 23, 2026	April 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 24, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 07, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 33 filings

Related Guides

Blog Categories

Continue your BBOT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.